TriSalus Q3 Revenue Up 11% but 2026 Guidance Cut to 2-6% Growth
TLSI sits 46% above its 52-week low of $2.2.
Summary
TriSalus reported Q3 2026 TriNav revenue of $12.9 million, up 11.3% year-over-year, with gross margin improving to 86.2% from 83.5%. Operating loss narrowed to $7.7 million from $9.0 million, and adjusted EBITDA loss improved to $4.7 million from $5.4 million, while the quarterly loss per share was 15 cents. The problem is the outlook: management cut full-year 2026 revenue guidance to $46 million to $48 million, only about 2% to 6% growth versus 2025, and the CEO acknowledged sales rep productivity has ramped slower than anticipated after the commercial footprint more than doubled in the first half. Offsetting that, CMS finalized a Medicare payment increase for HCPCS code C8004 from roughly $11,794 to $20,910 per procedure and set a national office-based lab payment of about $13,800 for G0577, both effective January 1, 2027 — a real reimbursement tailwind for the PEDD platform. Cash stood at $41.1 million at quarter end after a $46.0 million gross equity raise in Q1. The 8:30 AM ET call will be the first chance to gauge how much of the guidance cut is rep productivity versus underlying demand.
At the time of this announcement, TLSI was trading at $3.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198.3M. The 52-week trading range was $2.20 to $7.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.